MedTrace Logo

Analysis of the Therapeutic and Clinical Profile of Cannabinoid Treatments: A Real-World Study

NCT07362407 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 384

Last updated 2026-03-30

No results posted yet for this study

Summary

What is the purpose of this study? The use of medicinal cannabis has grown significantly in Brazil. However, because many patients use these products through "compassionate use" (when traditional treatments haven't worked), there is still a lack of large-scale data on how these treatments perform in daily life. This study, called CANAREAL, aims to track patients across Brazil to understand if cannabis-based products are truly effective and safe for treating various conditions, such as chronic pain, anxiety, and depression.

How will the study work? This is an observational study, which means the researchers will not provide the medication or change the treatment prescribed by the patient's doctor. Instead, we will simply "follow" the patient's journey for 6 months.

What will participants be asked to do? Participants will complete online questionnaires at different stages of their treatment. These tools will measure:

Quality of Life: How the treatment affects daily well-being.

Clinical Evolution: Changes in pain levels, anxiety, and depression symptoms.

Safety: Whether the patient experiences any side effects (adverse events).

Why is this study important? Unlike controlled laboratory tests, this "Real-World Study" captures the reality of diverse patients with different backgrounds and health needs. The information gathered will help doctors, patients, and health authorities in Brazil better understand the benefits and risks of cannabinoid therapy, leading to safer and more informed medical decisions in the future.

Conditions

  • Chronic Pain
  • Depression Disorders
  • Anxiety Disorders
  • Quality of Life
  • Cannabidiol Effects
  • Cannabinoids

Interventions

DIETARY_SUPPLEMENT

Participants are followed while using cannabis-based products (such as CBD or THC oils, extracts, or isolates) as prescribed by their own physicians for therapeutic purposes.

This is an observational study of patients using cannabis-based products as prescribed by their personal physicians. The investigators do not provide, prescribe, or assign any medication. Participants will use various formulations (such as CBD-dominant, THC-dominant, or balanced full-spectrum oils) administered according to their specific medical guidance. Data collection will focus on the natural course of the treatment, monitoring clinical evolution, quality of life, and safety through validated scales over a 6-month period.

Sponsors & Collaborators

  • HempMeds Brasil

    collaborator UNKNOWN

  • Santa Catarina Federal University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2026-09-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07362407 on ClinicalTrials.gov